7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate Official reprint from UpToDate www.uptodate.com 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved. Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg- Strauss) : Talmadge E King, Jr, MD : Kevin R Flaherty, MD, MS, Richard J Glassock, MD, MACP, Bruce S Bochner, MD : Paul Dieffenbach, MD All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jun 2023. This topic last updated: Jan 31, 2022. INTRODUCTION Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) abbreviated EGPA, which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral blood eosinophilia [1-9]. EGPA is classified as a vasculitis of the small and medium sized arteries, although the vasculitis is often not apparent in the initial phases of the disease. The most involved organ is the lung, followed by the skin. EGPA, however, can affect any organ system, including the cardiovascular, gastrointestinal, renal, and central nervous systems. Vasculitis of extrapulmonary organs is largely responsible for the morbidity and mortality associated with EGPA. The epidemiology, pathogenesis, and pathology of EGPA will be reviewed here. The clinical features, diagnosis, treatment and prognosis of this disorder, as well as the approach to patients with vasculitis and/or eosinophilia are discussed separately. (See "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)" and "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis" and "Overview of and approach to the vasculitides in adults" and "Approach to the patient with unexplained eosinophilia".) https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 1/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate EPIDEMIOLOGY The epidemiology of EGPA remains unclear because of the uncertainties related to diagnosis [10]. Approximately 10 percent of patients with a major form of vasculitis are recognized to have EGPA. Among the three anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (EGPA, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis), EGPA is least common [5]. Prevalence in Europe ranges from 10.7 to 14/million. In the United States, the prevalence is approximately 18/million. The highest prevalence reported is from Australia, at 22.3 cases/million [11]. (See "Overview of and approach to the vasculitides in adults".) The mean age at diagnosis of EGPA is 40 years [12]. EGPA is an uncommon cause of vasculitis in people older than 65 years, accounting for 5 percent of histologically proven vasculitis among 38 older adult patients with various systemic forms of angiitis [13,14]. EGPA is also rare in children and adolescents; when it does occur in this age group, it appears to follow a more aggressive course with prominent pulmonary and cardiovascular manifestations [15-17]. EGPA does not exhibit sex predominance [12,18]. A cross-sectional nationwide survey in Japan estimated the prevalence of EGPA at 17.8/1,000,000 [19]. The mean age at onset was 55 14 years ( SD). Among the patients tested for myeloperoxidase (MPO) anti-neutrophil cytoplasmic antibody (p-ANCA), 50 percent were positive; however, only 2.5 percent were positive for proteinase3 (PR3) c-ANCA. There was female predominance (2:1). PATHOGENESIS Abnormal immune function The exact pathogenesis of EGPA is unknown. Antineutrophil cytoplasmic antibodies (ANCA) are detected in about 40 to 60 percent of patients, and EGPA is classified among the ANCA-positive vasculitides [12,19-22]. However, it is not known whether ANCAs have a pathogenic role in EGPA or whether they just reflect one end of the spectrum of EGPA manifestations. (See "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Antineutrophil cytoplasmic antibodies' and "Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis".) In addition, EGPA is characterized by several other abnormalities in immune function [23-26]: The prominence of allergic features (allergic rhinitis, asthma, and positive skin tests) suggests heightened Th2 immunity [25]. https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 2/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate Pulmonary angiocentric granulomatosis suggests heightened Th1 immunity [26]. The number of peripheral blood CD4+CD25+ T cells (T regulatory cells) that produce IL-10 were decreased in patients with EGPA compared with asthma or chronic eosinophilic pneumonia and were increased in patients with EGPA in remission [27]. These observations suggest that T regulatory cells may influence which patients with asthma and chronic eosinophilic pneumonia will develop active EGPA. Abnormal eosinophil function is likely due to a combination of increased eosinophil recruitment by Th2 cytokines and decreased eosinophil apoptosis [23]. Altered humoral immunity is suggested by hypergammaglobulinemia, especially IgE, and rheumatoid factor positivity in some patients. Genetic factors Genetic factors may also play a role. In a study of 48 patients and 350 healthy controls, both HLA-DRB1*07 and HLA-DRB4 were more prevalent among patients with EGPA and HLA-DRB4 correlated with the number of vasculitic manifestations [28]. A genome wide association study (GWAS) that included 676 patients with EGPA and 6809 healthy controls identified genetic distinctions between ANCA-myeloperoxidase positive (MPO+) and ANCA-negative disease, correlating with different clinical features [21]. Variants in the regions of BCL2L11, LPP, C5orf56-IRF1-IL5, and 10p14 were associated with EGPA, consistent with a polygenic disease and suggesting a role for susceptibility to eosinophilia in EGPA pathogenesis. When comparing MPO+ patients with MPO- patients, the study noted an association with HLA- DQ in MPO+ EGPA that was not present in MPO- EGPA, suggesting two potential subtypes of EGPA: an eosinophilic autoimmune (MPO+) disease and a mucosal barrier dysfunction (MPO-) subtype. Polymorphisms in the interleukin (IL)-10 gene have been associated with EGPA. In a study of 103 patients with EGPA, genotyping identified three single nucleotide polymorphisms (SNPs) relating to the interleukin (IL)-10 gene [29]. The IL-10 -3575/-1082/-592 TAC haplotype (part of IL 10.2) was strongly associated with EGPA (OR=2.16) and negatively associated with granulomatosis with polyangiitis (GPA). Three-fourths of the patients were ANCA negative. (See "Genetics of asthma".) ASSOCIATION WITH MEDICATIONS Several medications have been associated with the appearance of EGPA. In the case of asthma therapies such as leukotriene modifying agents, inhaled glucocorticoids, and omalizumab, it https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 3/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate appears that this is more likely an unmasking of underlying disease rather than a causal relationship, as described below. Leukotriene modifying agents EGPA has been reported as a rare complication in patients with systemic glucocorticoid-dependent asthma who were treated with a leukotriene modifying agent (LTMA; eg, zafirlukast, montelukast, pranlukast, zileuton), usually in the setting of reduction in the dose of oral glucocorticoids [30-43]. It is believed that LTMAs may unmask underlying EGPA in the following ways [44,45]: Glucocorticoid withdrawal is facilitated by LTMA therapy, leading to elaboration of EGPA disease manifestations. Patients who have undiagnosed but escalating EGPA are prescribed a LTMA because of worsening symptoms. The LTMA is insufficient to control EGPA and the disease becomes manifest (ie, confounding by indication). However, it is difficult to completely exclude the possibility that LTMAs play a causal role in the development of EGPA in some patients [30-42,46]. Inhaled glucocorticoids The onset of clinical evidence of EGPA has also occurred when the addition or increase in inhaled glucocorticoids allowed reduction in the dose of systemic glucocorticoids, which in turn led to an "unmasking" of EGPA symptoms as described above [38]. Omalizumab EGPA has also been noted in patients receiving omalizumab (a humanized anti- IgE antibody) for treatment of severe asthma [47-49]. The appearance of EGPA symptoms preceded treatment with omalizumab or coincided with tapering of systemic glucocorticoids, suggesting that omalizumab had been added in the setting of escalating EGPA or that it allowed "unmasking" of underlying EGPA. It remains unclear whether or not omalizumab can be used in the treatment of EGPA [50]. (See "Anti-IgE therapy", section on 'Other issues'.) Cocaine An unusual EGPA-like vasculitis has been associated with the use of free base cocaine [51]. The diagnosis of EGPA in patients who use cocaine is a complicated issue because both acute and chronic eosinophilic pneumonia are manifestations of cocaine toxicity and antineutrophil cytoplasmic antibodies are detected in the majority of patients with cocaine- induced midline destructive lesions of the nose [52]. (See "Pulmonary complications of cocaine use", section on 'Acute pulmonary toxicity and crack lung' and "Pulmonary complications of cocaine use", section on 'Chronic toxicity'.) The anti-neutrophil cytoplasmic antibodies (ANCAs) associated with cocaine-induced midline destructive lesions appear to be different from those associated with EGPA. ANCAs from patients https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 4/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate with cocaine-induced midline destructive lesions typically recognize human neutrophil elastase as the target antigen, although autoantibodies to proteinase 3 and other serine proteases are also seen [53]. In contrast, ANCAs from patients with EGPA commonly react to myeloperoxidase and not human neutrophil elastase [52]. Sera from patients with granulomatosis with polyangiitis (GPA) typically react with proteinase 3, but not human neutrophil elastase. (See "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg- Strauss)", section on 'Antineutrophil cytoplasmic antibodies'.) PATHOLOGY The major histopathologic findings of EGPA from any affected organ includes the following, although they may not all be present (especially in patients who have been partially treated) [54- 56]: Eosinophilic infiltration Prominent and sometimes quite extensive areas of necrosis An eosinophilic, giant cell vasculitis, especially of the small arteries and veins Interstitial and perivascular necrotizing granulomas ( picture 1) Pathologic findings in different organs include: In the lung, asthmatic bronchitis, eosinophilic pneumonia, extravascular granulomas, or vasculitis (affecting arteries, veins, or capillaries) may be seen. In some cases, the inflammatory lesions extend along the pleura and interlobular septa. The granulomas in EGPA typically have a border of palisading histiocytes and multinucleated giant cells surrounding a central necrotic zone consisting of the necrotic eosinophils. The vascular infiltrates are often composed of chronic inflammatory cells, eosinophilic infiltrates, epithelioid histiocytes, multinucleated giant cells and/or neutrophils. Diffuse pulmonary hemorrhage and capillaritis may be seen. In the kidney, necrotizing crescentic glomerulonephritis is the most common finding, but eosinophilic interstitial nephritis, mesangial glomerulonephritis, and focal segmental glomerulosclerosis are also seen [57,58]. Endomyocardial biopsies typically reveal eosinophilic infiltration and endomyocarditis, but not vasculitis [59]. Skin biopsy typically reveals a leukocytoclastic vasculitis with eosinophil infiltration [60]. Palisading granulomas and/or eosinophilic infiltration of dermal nerve fibers may also be https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 5/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate noted. The histopathologic findings may vary with the phase of disease [61,62]. (See "Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Phases of disease'.) During the prevasculitic phase, tissue infiltration by eosinophils may be present without overt vasculitis. During the vasculitic phase, a nondestructive infiltration of vessel walls is noted and may be more common than a necrotizing vasculitis. In the postvasculitic phase, healed vascular lesions resembled organized thrombi, but are associated with extensive destruction of the elastica. In this later phase, eosinophilic infiltration may be absent. SOCIETY GUIDELINE LINKS Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Vasculitis".) SUMMARY AND RECOMMENDATIONS Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) abbreviated EGPA, which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral blood eosinophilia. (See 'Introduction' above.) The exact etiology is unknown. Antineutrophil cytoplasmic antibodies (ANCA) are detected in about 40 to 60 percent of patients and EGPA is classified among the ANCA-positive vasculitides. Several other abnormalities in immunologic function occur in EGPA, including heightened Th1 and Th2 lymphocyte function, increased eosinophil recruitment and decreased eosinophil apoptosis. (See 'Pathogenesis' above.) Genetic factors such as human leukocyte antigen (HLA) class and certain interleukin-10 polymorphisms may play a role in EGPA pathogenesis. (See 'Genetic factors' above.) Several asthma medications, such as the leukotriene modifying agents, inhaled glucocorticoids, and omalizumab, have been associated with the appearance of EGPA. https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 6/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate However, it appears that the association is most likely due to unmasking of the underlying disease or intensification of therapy in a patient with escalating EGPA, rather than a causal relationship. (See 'Association with medications' above.) A EGPA-like illness can rarely occur after the use of free base cocaine. However, the ANCAs associated with cocaine use recognize different target proteases than the typical ANCAs associated with EGPA. (See 'Cocaine' above.) The major histopathologic findings of EGPA from any affected organ include the following, although they may not all be present: eosinophilic infiltration; prominent and sometimes extensive areas of necrosis; an eosinophilic, giant cell vasculitis, especially of the small arteries and veins; and also interstitial and perivascular necrotizing granulomas ( picture 1). (See 'Pathology' above.) Use of UpToDate is subject to the Terms of Use. REFERENCES 1. CHURG J, STRAUSS L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27:277. 2. Churg A. Pulmonary angiitis and granulomatosis revisited. Hum Pathol 1983; 14:868. 3. Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23:355. 4. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25. 5. Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 2006; 27:148. 6. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long- term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26. 7. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65. 8. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094. 9. Szczeklik W, Jakie a B, Adamek D, Musia J. Cutting edge issues in the Churg-Strauss syndrome. Clin Rev Allergy Immunol 2013; 44:39. 10. Schwartz RA, Churg J. Churg-Strauss syndrome. Br J Dermatol 1992; 127:199. https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 7/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate 11. Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology (Oxford) 2020; 59:iii42. 12. Conron M, Beynon HL. Churg-Strauss syndrome. Thorax 2000; 55:870. 13. Mouthon L, Le Toumelin P, Andre MH, et al. Polyarteritis nodosa and Churg-Strauss angiitis: characteristics and outcome in 38 patients over 65 years. Medicine (Baltimore) 2002; 81:27. 14. Abril A, Calamia KT, Cohen MD. The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 2003; 33:106. 15. Zwerina J, Eger G, Englbrecht M, et al. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum 2009; 39:108. 16. Gendelman S, Zeft A, Spalding SJ. Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort. J Rheumatol 2013; 40:929. 17. Iudici M, Pu chal X, Pagnoux C, et al. Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry. Arthritis Rheumatol 2015; 67:1959. 18. Harrold LR, Andrade SE, Go AS, et al. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005; 32:1076. 19. Sada KE, Amano K, Uehara R, et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol 2014; 24:640. 20. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926. 21. Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 2019; 10:5120. 22. Moiseev S, Bossuyt X, Arimura Y, et al. International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med 2020. 23. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003; 21:S69. 24. Zwerina J, Axmann R, Jatzwauk M, et al. Pathogenesis of Churg-Strauss syndrome: recent insights. Autoimmunity 2009; 42:376. 25. Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41:445. https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 8/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate 26. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg- Strauss syndrome. Ann N Y Acad Sci 2005; 1051:121. 27. Tsurikisawa N, Saito H, Tsuburai T, et al. Differences in regulatory T cells between Churg- Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 2008; 122:610. 28. Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg- Strauss syndrome. Arthritis Rheum 2007; 56:3159. 29. Wieczorek S, Hellmich B, Arning L, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 2008; 58:1839. 30. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455. 31. Franco J, Art s MJ. Pulmonary eosinophilia associated with montelukast. Thorax 1999; 54:558. 32. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999; 353:725. 33. Kinoshita M, Shiraishi T, Koga T, et al. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol 1999; 103:534. 34. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999; 8:179. 35. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117:708. 36. Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 2008; 63:677. 37. D'Cruz DP, Barnes NC, Lockwood CM. Difficult asthma or Churg-Strauss syndrome? BMJ 1999; 318:475. 38. Le Gall C, Pham S, Vignes S, et al. Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. Eur Respir J 2000; 15:978. 39. Cooper SM, Libman BS, Lazarovich M. Churg-strauss syndrome in a group of patients receiving fluticasone for asthma. J Rheumatol 2002; 29:2651. https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 9/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate 40. Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax 2000; 55:805. 41. Katsura T, Yoshida F, Takinishi Y. The Churg-Strauss syndrome after pranlukast treatment in a patient not receiving corticosteroids. Ann Intern Med 2003; 139:386. 42. Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63:883. 43. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284. 44. Specks, U. Pulmonary vasculitis. In: Interstitial Lung Disease, 5th, Schwarz, MI, King, TE Jr (E ds), People's Medical Publishing House, Shelton, CT, USA 2011. p.765. 45. Keogh KA. Leukotriene receptor antagonists and Churg-Strauss syndrome: cause, trigger or merely an association? Drug Saf 2007; 30:837. 46. Bibby S, Healy B, Steele R, et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010; 65:132. 47. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-strauss syndrome in patients treated with omalizumab. Chest 2009; 136:507. 48. Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 2008; 121:253. 49. Nazir S, Tachamo N, Fareedy SB, et al. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol 2017; 118:372. 50. Basta F, Mazzuca C, Nucera E, et al. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature review. Clin Exp Rheumatol 2020; 38 Suppl 124:214. 51. Orriols R, Mu oz X, Ferrer J, et al. Cocaine-induced Churg-Strauss vasculitis. Eur Respir J 1996; 9:175. 52. Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50:2954. 53. Peikert T, Finkielman JD, Hummel AM, et al. Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. Arthritis Rheum 2008; 58:1546. 54. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14:1284. https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 10/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate 55. Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung. A review. Am J Clin Pathol 2000; 114:767. 56. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990; 33:1074. 57. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47:770. 58. Clutterbuck EJ, Evans DJ, Pusey CD. Renal involvement in Churg-Strauss syndrome. Nephrol Dial Transplant 1990; 5:161. 59. Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236. 60. Kawakami T, Soma Y, Kawasaki K, et al. Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome. Arch Dermatol 2005; 141:873. 61. Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108:320. 62. Hueto-Perez-de-Heredia JJ, Dominguez-del-Valle FJ, Garcia E, et al. Chronic eosinophilic pneumonia as a presenting feature of Churg-Strauss syndrome. Eur Respir J 1994; 7:1006. Topic 4363 Version 21.0 https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 11/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate GRAPHICS Granuloma in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Low power photomicrograph shows the palisading granuloma of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) characterized by an area of necrobiosis (arrow) permeated by disintegrating neutrophils and palisaded by a histiocytic infiltrate. There may or may not be an accompanying vasculitis. Courtesy of Cynthia Magro, MD. Graphic 50143 Version 3.0 https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 12/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate Contributor Disclosures Talmadge E King, Jr, MD No relevant financial relationship(s) with ineligible companies to disclose. Kevin R Flaherty, MD, MS Grant/Research/Clinical Trial Support: Boehringer Ingelheim [IPF]. Consultant/Advisory Boards: Arrowhead [Interstitial lung disease]; AstraZeneca [Interstitial lung disease]; Bellerophon [Interstitial lung disease]; CSL Behring [Interstitial lung disease]; Daewong Pharmaceuticals [Interstitial lung disease]; DevPro [Interstitial lung disease]; Dispersol [Interstitial lung disease]; Fibrogen [Interstitial lung disease]; Horizon [Interstitial lung disease]; Immunmet [Interstitial lung disease]; Insilco [Interstitial lung disease]; Lupin [Interstitial lung disease]; NeRRe Therapeutics [Interstitial lung disease]; Pliant [Interstitial lung disease]; Polarean [Interstitial lung disease]; PureHealth [Interstitial lung disease]; PureTech [Interstitial lung disease]; Respivant [Interstitial lung disease]; Roche/Genentech [Interstitial lung disease]; Shionogi [Interstitial lung disease]; Sun Pharmaceuticals [Interstitial lung disease]; Trevi Pharmaceuticals [Interstitial lung disease]; United Therapeutics [Interstitial lung disease]; Vicore [Interstitial lung disease]. All of the relevant financial relationships listed have been mitigated. Richard J Glassock, MD, MACP Employment: Karger Publishers [Associate Editor of Nephrology Viewpoints blog for American Journal of Nephrology]. Equity Ownership/Stock Options: Reata [Alport syndrome, pulmonary hypertension, diabetic nephropathy]. Consultant/Advisory Boards: Alexion [Pharmaceutical development]; Arrowhead [Complement-mediated GN]; Aurinia [Voclosporin, lupus nephritis]; BioCryst [IgA nephropathy and C3GN]; Calliditas [IgA nephropathy]; Chinook [Pharmaceutical development]; Equillium Bio [IgA nephropathy, lupus nephritis]; Horizon Pharma [IgA nephropathy]; Ionis [IgA N and anti-PLA2R antibody- associated MN]; National Institutes of Health [NEPTUNE study chair]; Nephro-Sys [Novel agent for GN]; Novartis [IgA nephropathy]; Omeros [IgA nephropathy]; Otsuka Pharmaceuticals [IgA nephropathy]; Renasight [Genetics in kidney disease]; River Renal [R3RE-01 in primary FSGS]; Therini Bio [Novel agent for GN]; Travere [Focal segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy]; Vera pharamaceuticals [Pharmaceutical development]; Vertex Inc [Novel drug compound for treatment of APOL1-related FSGS]. Speaker's Bureau: Aurinia [Lupus nephritis]. Other Financial Interest: American Association of Kidney Patients [Board member; non-profit voluntary health organization]; Oxford Medical Publishers [Primary glomerular disease]; University Kidney Research Organization [Nephrology]. All of the relevant financial relationships listed have been mitigated. Bruce S Bochner, MD Equity Ownership/Stock Options: Allakos [Eosinophil and mast cell-related diseases]. Patent Holder: anti-Siglec-8 antibodies [Lirentelimab/AK002, eosinophil and mast cell-associated disease]. Grant/Research/Clinical Trial Support: NIAID [Siglec-6, Siglec-8, asthma, anaphylaxis, food allergy, Bruton's tyrosine kinase, mastocytosis, nanoparticle targeting]. Consultant/Advisory Boards: Acelyrin, Inc [Eosinophil and mast cell-related diseases]; Allakos [Eosinophil and mast cell-related diseases]; Blueprint Medicines [Eosinophil and mast cell-related diseases]; Lupagen, Inc [Eosinophil and mast cell-related diseases]; Regeneron [Eosinophil and mast cell-related diseases]; Sanofi [Eosinophil and mast cell-related diseases]; StealthBio Therapeutics [Eosinophil and mast cell-related diseases]; Third Harmonic Bio [Eosinophil and mast cell-related diseases]. Other Financial Interest: Elsevier [Publication royalties]; Johns Hopkins University School of Medicine [Royalties related to licensing of intellectual property to Allakos, Inc]. All of the relevant financial relationships listed have been mitigated. Paul Dieffenbach, MD No relevant financial relationship(s) with ineligible companies to disclose. Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence. https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 13/14 7/7/23, 11:16 AM Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) - UpToDate Conflict of interest policy https://www.uptodate.com/contents/epidemiology-pathogenesis-and-pathology-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss/print 14/14